(ARMK) Aramark Holdings - Overview
Stock: Food Services, Facilities Management, Catering, Vending, Laundry
| Risk 5d forecast | |
|---|---|
| Volatility | 26.1% |
| Relative Tail Risk | -6.13% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.40 |
| Alpha | -0.05 |
| Character TTM | |
|---|---|
| Beta | 0.873 |
| Beta Downside | 0.976 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.63% |
| CAGR/Max DD | 0.59 |
EPS (Earnings per Share)
Revenue
Description: ARMK Aramark Holdings January 02, 2026
Aramark (NYSE: ARMK) delivers food and facilities services across education, healthcare, business-and-industry, sports, leisure, and corrections markets, operating through two geographic segments: Food & Support Services United States and Food & Support Services International.
Its portfolio includes managed dining, catering, and retail food services; non-clinical nutrition and procurement for hospitals; and a broad suite of facility-management functions such as custodial, energy management, grounds keeping, and capital-project oversight. The company also runs on-site restaurants, vending, concessions, and lodging services at sports and entertainment venues, plus correctional food, commissaries, and laundry operations.
Key recent metrics (FY 2023): revenue of roughly $15.8 billion, operating margin around 6 %, and earnings per share of $2.45. The business is heavily weighted toward education (≈ 45 % of revenue) and healthcare (≈ 30 %), making enrollment trends and hospital admission rates material drivers of top-line growth.
Economic sensitivities include rising labor costs and food-price inflation, which compress margins unless offset by price-pass-through or efficiency initiatives. A notable strategic shift was the 2021 spin-off of its uniform services, sharpening focus on core food-and-facility operations and improving cash-flow visibility.
Sector-wide, institutional food service firms are benefitting from increased demand for outsourced dining solutions as employers and institutions seek cost certainty and compliance with evolving health-safety standards.
For a deeper quantitative dive, the ValueRay platform offers granular segment-level metrics and peer comparisons that can help validate these observations.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 316.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.97 > 1.0 |
| NWC/Revenue: 4.14% < 20% (prev -1.15%; Δ 5.29% < -1%) |
| CFO/TA 0.05 > 3% & CFO 726.0m > Net Income 316.9m |
| Net Debt (6.40b) to EBITDA (1.27b): 5.04 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (266.3m) vs 12m ago -0.87% < -2% |
| Gross Margin: 6.98% > 18% (prev 0.08%; Δ 689.9% > 0.5%) |
| Asset Turnover: 143.1% > 50% (prev 138.1%; Δ 5.05% > 0%) |
| Interest Coverage Ratio: 2.20 > 6 (EBITDA TTM 1.27b / Interest Expense TTM 355.0m) |
Altman Z'' 0.94
| A: 0.06 (Total Current Assets 3.63b - Total Current Liabilities 2.86b) / Total Assets 13.54b |
| B: 0.04 (Retained Earnings 515.8m / Total Assets 13.54b) |
| C: 0.06 (EBIT TTM 779.7m / Avg Total Assets 13.12b) |
| D: 0.04 (Book Value of Equity 368.8m / Total Liabilities 10.31b) |
| Altman-Z'' Score: 0.94 = BB |
Beneish M -2.80
| DSRI: 1.06 (Receivables 2.50b/2.20b, Revenue 18.79b/17.55b) |
| GMI: 1.19 (GM 6.98% / 8.34%) |
| AQI: 0.97 (AQ_t 0.54 / AQ_t-1 0.56) |
| SGI: 1.07 (Revenue 18.79b / 17.55b) |
| TATA: -0.03 (NI 316.9m - CFO 726.0m) / TA 13.54b) |
| Beneish M-Score: -2.80 (Cap -4..+1) = A |
What is the price of ARMK shares?
Over the past week, the price has changed by +4.20%, over one month by +4.36%, over three months by +9.28% and over the past year by +11.37%.
Is ARMK a buy, sell or hold?
- StrongBuy: 8
- Buy: 4
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ARMK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 46.6 | 14% |
| Analysts Target Price | 46.6 | 14% |
ARMK Fundamental Data Overview February 21, 2026
P/E Forward = 17.8571
P/S = 0.5671
P/B = 3.1936
P/EG = 0.9872
Revenue TTM = 18.79b USD
EBIT TTM = 779.7m USD
EBITDA TTM = 1.27b USD
Long Term Debt = 6.21b USD (from longTermDebt, last quarter)
Short Term Debt = 98.8m USD (from shortTermDebt, last quarter)
Debt = 6.84b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.40b USD (from netDebt column, last quarter)
Enterprise Value = 17.05b USD (10.65b + Debt 6.84b - CCE 439.6m)
Interest Coverage Ratio = 2.20 (Ebit TTM 779.7m / Interest Expense TTM 355.0m)
EV/FCF = 66.30x (Enterprise Value 17.05b / FCF TTM 257.1m)
FCF Yield = 1.51% (FCF TTM 257.1m / Enterprise Value 17.05b)
FCF Margin = 1.37% (FCF TTM 257.1m / Revenue TTM 18.79b)
Net Margin = 1.69% (Net Income TTM 316.9m / Revenue TTM 18.79b)
Gross Margin = 6.98% ((Revenue TTM 18.79b - Cost of Revenue TTM 17.47b) / Revenue TTM)
Gross Margin QoQ = 6.01% (prev 5.78%)
Tobins Q-Ratio = 1.26 (Enterprise Value 17.05b / Total Assets 13.54b)
Interest Expense / Debt = 1.30% (Interest Expense 88.9m / Debt 6.84b)
Taxrate = 28.85% (39.1m / 135.6m)
NOPAT = 554.7m (EBIT 779.7m * (1 - 28.85%))
Current Ratio = 1.27 (Total Current Assets 3.63b / Total Current Liabilities 2.86b)
Debt / Equity = 2.13 (Debt 6.84b / totalStockholderEquity, last quarter 3.21b)
Debt / EBITDA = 5.04 (Net Debt 6.40b / EBITDA 1.27b)
Debt / FCF = 24.87 (Net Debt 6.40b / FCF TTM 257.1m)
Total Stockholder Equity = 3.12b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.41% (Net Income 316.9m / Total Assets 13.54b)
RoE = 10.17% (Net Income TTM 316.9m / Total Stockholder Equity 3.12b)
RoCE = 8.36% (EBIT 779.7m / Capital Employed (Equity 3.12b + L.T.Debt 6.21b))
RoIC = 6.01% (NOPAT 554.7m / Invested Capital 9.24b)
WACC = 5.92% (E(10.65b)/V(17.49b) * Re(9.13%) + D(6.84b)/V(17.49b) * Rd(1.30%) * (1-Tc(0.29)))
Discount Rate = 9.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.39%
[DCF Debug] Terminal Value 87.39% ; FCFF base≈300.2m ; Y1≈339.7m ; Y5≈460.7m
Fair Price DCF = 26.87 (EV 13.46b - Net Debt 6.40b = Equity 7.06b / Shares 262.8m; r=5.92% [WACC]; 5y FCF grow 15.35% → 2.90% )
EPS Correlation: 51.87 | EPS CAGR: 25.13% | SUE: 0.0 | # QB: 0
Revenue Correlation: 72.77 | Revenue CAGR: 6.17% | SUE: 0.97 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.47 | Chg30d=-0.005 | Revisions Net=-5 | Analysts=12
EPS current Year (2026-09-30): EPS=2.23 | Chg30d=+0.008 | Revisions Net=+3 | Growth EPS=+22.2% | Growth Revenue=+7.0%
EPS next Year (2027-09-30): EPS=2.62 | Chg30d=+0.026 | Revisions Net=+6 | Growth EPS=+17.6% | Growth Revenue=+6.2%